AC
ATXS

Armistice Capital’s Astria Therapeutics ATXS Stock Holding History

Armistice Capital’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,578,000
Closed -$12.1M – 346
2023
Q4 		$12.1M Buy
+1,578,000
New +$8.73M 0.17% 73
2018
Q3 		– Sell
-33,333
Closed -$1.92M – 80
2018
Q2 		$1.92M Buy
+33,333
New +$3.07M 0.13% 66

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Armistice Capital's ATXS Position: Q1 2024 in Review

Armistice Capital sold out of Astria Therapeutics (ATXS) in Q1 2024, closing a stake of 1,578,000 shares — an estimated $12.1M sold.

Armistice Capital first reported a position in ATXS in Q2 2018 and held it in 2 quarters. The position peaked at $12.1M in Q4 2023. 102 funds tracked by Wall St. Rank hold ATXS as of Q1 2024.

  • Armistice Capital reported no remaining Astria Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Armistice Capital sold 1,578,000 Astria Therapeutics shares in Q1 2024, an estimated $12.1M.
  • Armistice Capital first reported a position in Astria Therapeutics in Q2 2018 and held it in 2 quarters.
  • Armistice Capital's Astria Therapeutics position peaked at $12.1M in Q4 2023.
  • 102 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2024.

Based on Armistice Capital's 13F filing for Q1 2024, filed 15 May 2024.